Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Competitive Edge | Learn how Nuvalent's focus on improved safety profiles and efficacy could differentiate its therapies in the crowded oncology landscape |
Financial Outlook | Analysts maintain a positive stance with a $100 price target, despite current unprofitability. EPS projections for FY2025 stand at -$5.07 |
Market Potential | Delve into Nuvalent's strategy to capture both treatment-experienced and first-line markets, potentially positioning it as a leader in targeted therapies |
Pipeline Progress | Explore Nuvalent's advancing oncology pipeline, with zidesamtinib and neladalkib showing promise in ROS1 and ALK-positive NSCLC clinical trials |
Metrics to compare | NUVL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.9x | −6.1x | −0.5x | |
PEG Ratio | 0.41 | −0.09 | 0.00 | |
Price / Book | 6.8x | 5.3x | 2.6x | |
Price / LTM Sales | - | 25.2x | 3.3x | |
Upside (Analyst Target) | 30.1% | 72.7% | 43.8% | |
Fair Value Upside | Unlock | −5.5% | 5.3% | Unlock |